Murillo-Zamora Efrén, Jiménez-Álvarez Alicia
Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 19, Departamento de Epidemiología. Colima, Colima, México.
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Departamento de Pediatría. Villa de Álvarez, Colima, México.
Rev Med Inst Mex Seguro Soc. 2022 Aug 31;60(5):511-516.
A segment of children and adolescents with coronavirus disease 2019 (COVID-19) develops pneumonia and published evidence regarding its prognostic factors in this specific population is scarce.
To characterize the survival of children and adolescents hospitalized for pneumonia related to COVID-19, as well as to evaluate prognostic factors for disease's outcomes.
A cohort study was performed in Mexico and data from hospitalized children and adolescents with COVID-19 related pneumonia were analyzed. We used the Kaplan-Meier method to estimate survival functions and 95% confidence intervals (95% CI), as well as Cox proportional-hazards regressions to evaluate the association of the evaluated exposures with the outcomes of disease.
A total of 1423 patients were recruited for a follow-up of 15,188 person-days and the overall rate of in-hospital mortality (n = 208) was 13.7 per 1000 person-days. The survival function was 96.5% (95% CI 95.2-97.4%) and 69.3% (95% CI 63.9-74.0) of hospital stay, respectively. In multiple analysis, the history of immunosuppression was associated with an increased risk of a fatal outcome (hazard ratio [HR] = 2.70, IC 95% 1.38-5.30).
We characterized the survival of a large cohort of children and adolescents with COVID-19 related pneumonia. The presented findings suggest that minors with a history of immunosuppression and pneumonia have an increased risk of fatal outcome.
一部分患有2019冠状病毒病(COVID-19)的儿童和青少年会发展为肺炎,而关于这一特定人群预后因素的已发表证据很少。
描述因COVID-19相关肺炎住院的儿童和青少年的生存情况,并评估疾病结局的预后因素。
在墨西哥进行了一项队列研究,分析了因COVID-19相关肺炎住院的儿童和青少年的数据。我们使用Kaplan-Meier方法估计生存函数和95%置信区间(95%CI),以及Cox比例风险回归来评估所评估暴露因素与疾病结局的关联。
共招募了1423例患者,随访15188人日,住院总死亡率(n = 208)为每1000人日13.7例。住院期间的生存函数分别为96.5%(95%CI 95.2 - 97.4%)和69.3%(95%CI 63.9 - 74.0)。在多因素分析中,免疫抑制史与致命结局风险增加相关(风险比[HR]=2.70,95%CI 1.38 - 5.30)。
我们描述了一大群患有COVID-19相关肺炎的儿童和青少年的生存情况。研究结果表明,有免疫抑制史且患肺炎的未成年人致命结局风险增加。